ECLIPSE AF, evaluated the safety and performance of the CardioFocus Centauri system with commercial focal ablation catheters. The first-in-human study enrolled 82 patients treated across two centers in Europe. Centauri, which holds CE mark approval, remains investigational in the U.S.

The open-platform design supports focal contact force catheter workflows. It leverages a custom monopolar waveform designed to achieve transmural lesions while eliminating microbubbles and muscle stimulation. The system enables durable PFA lesions while enhancing procedural efficiency, safety and patient outcomes.

CardioFocus conducted the study of Centauri with the Abbott TactiCath, Boston Scientific IntellaNav StablePoint and Johnson & Johnson ThermoCool SmartTouch ablation catheters.